



**UK Hub for Advanced Long-acting
Therapeutics (HALo)**

Charter Partnership

Version Number	1.0
Date agreed	September 2025
Agreed by	HALo Academic Partners
Review date	September 2027

Charter Partnership with HALo

On behalf of HALo, the UK Hub for Advanced Long-acting Therapeutics, we welcome your organisation to join us on this important endeavour.

The ambition of HALo is to establish the UK as the world leader in long-acting medicines through an evidence-based foundation: advancing fundamental physical science, accelerating proof-of-concept development through involvement and engagement with patients, the public, and clinicians, creating future paradigms, and enabling translation pathways from development to clinical application.

HALo will conduct world-leading physical science research that will:

- Accelerate the development of long-acting therapeutics
- Advocate for a national strategy on long-acting therapeutics
- Create an evidence-based pathway for a national translational ecosystem that enables scale-up of industrial and academic long-acting therapeutic candidates, from pre-clinical proof-of-concept through to a UK-wide manufacturing infrastructure capable of producing Good Manufacturing Practice medicinal long-acting therapeutics products
- Enable a regulatory environment that can provide rapid clinical evaluation

HALo has established partnerships with numerous pharmaceutical companies (start-ups to multinationals), contract development and manufacturing organisations, formulation ingredient manufacturers, and some of the largest hospitals in the UK. We will create forums for patients, contract development and manufacturing organisations, and industry, and alongside additional partners will advocate for a national strategy that facilitates both the economic and healthcare capabilities of long-acting therapeutics. Future national healthcare provision will require long-acting therapeutics to overcome unmet clinical needs that conventional medicines cannot meet, whilst expanding treatment options for patients and clinicians. HALo will address key technology questions, establish long-acting therapeutics awareness, and ensure patient involvement in future long-acting therapeutic development.

Achieving our ambition is a huge task and we cannot achieve this alone. We need Charter Partners to help co-create solutions with us. We envisage that our Charter Partners will be able to provide insights into the needs of local populations and their healthcare challenges, as well as collaborate in future research and innovation projects within the field of long-acting therapeutics.

Charter Partnership with HALo

This Charter is not a legally binding document, but instead a way of bringing organisations together that share the same goals.

Organisations are free to leave at any time and may do so by notifying HALo in writing of their decision. If you have contracted to join a project, your ongoing participation in that project will not be affected by leaving, and your participation in the project will continue to be governed by the terms of your project agreement.

To be a Charter Partner all we ask is that each organisation:

- Is currently working within the long-acting therapeutics space, or has plans to in the future
- Is committed to improving the health and prosperity of communities in the UK and globally
- Is prepared to engage in open dialogue around the challenges and solutions in long-acting therapeutics
- Supports the ambition of the partnership to generate data and technologies that enhance the UK's health and prosperity and improve lives for all relevant patient groups across the world
- Works collaboratively to enhance research and innovation within the UK
- Provides a named person to represent their organisation
- Commits to being an Ambassador for the Charter - permitting your organisation's name & logo to be used publicly

In return HALo will:

- Invite the named person from your organisation to join the HALo Industry Forum or CDMO Forum, whichever is most relevant to ensure strategic alignment between stakeholders
- Provide access to relevant early data, where possible, provided it is not under embargo, patent protected or will infringe on intellectual property rights
- Invite your organisation to collaborate on research or innovation projects
- Regularly update your organisation on HALo's activities and provide early access to outputs through the HALo mailing list
- Engage with you in the development of key decision papers for submission to national Government bodies
- Seek your opinion and represent that opinion accurately on matters concerning the future of long-acting therapeutics